The Effect of Topical Rho-kinase Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal Dystrophy

Launched by UNIVERSITY HOSPITAL DUBRAVA · May 5, 2025

Keywords

ClinConnect Summary

The purpose of this study is to evaluate the effect of topical Rho-kinase (ROCK) inhibitors on corneal endothelial cells (CECs) after cataract surgery in patients with cataract, glaucoma and Fuchs Endothelial Corneal Dystrophy (FECD). The study was approved by Ethics Committee of University Hospital Dubrava and will be conducted in accordance with tenets of the Declaration of Helsinki. Informed consent will be obtained from all individual participants included in the study.

Patients with glaucoma and FECD that require cataract surgery will be recruited. The inclusion criteria will be: age ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • age between 40 and 90 years;
• • diagnosis of FECD and glaucoma;
• • cataract grade II nuclear/cortical or posterior subcapsular (Lens Opacity Classification System III \[LOCS III\].
• Exclusion criteria:
• • other anterior segment pathology (pseudoexfoliation syndrome, corneal opacities);
• • ocular surface inflammation;
• • intraoperative complications (posterior capsular rupture, vitreous loss, IOL not implanted in the capsular bag);
• • previous ocular trauma or intraocular surgery